Skip to content
  1. Home/
  2. Latest news/
  3. Janssen Pharmaceuticals releases a 2016 U.S. Transparency Report
A photo of a pharmacist holding a bottle of medicine

Janssen Pharmaceuticals releases a 2016 U.S. Transparency Report

Jennifer Taubert, Company Group Chairman, Pharmaceuticals, The Americas, explains why Janssen is sharing information around its medication pricing and other business practices.

Johnson & Johnson has a legacy of leadership when it comes to transparency. And the Janssen Pharmaceutical Companies of Johnson & Johnson recognize that consumers in the U.S. are particularly concerned about the high cost of healthcare these days. That’s why the company just released a 2016 U.S. Transparency Report that includes information on pricing and other business practices, covering everything from discovery to the commercialization of pharmaceuticals.

“Our hope is that this report will address questions people may have, and that it will lead to more discussion about how we can work together to move toward a more value-based healthcare system—one that delivers what we all want: greater access to care at a more manageable cost, and, most importantly, better health for us all,” says Jennifer Taubert, Company Group Chairman, Pharmaceuticals, The Americas.

Watch this video of Taubert to learn more about the 2016 U.S. Transparency Report and how it can help better inform consumers.

hqdefault.jpg
2016 U.S. Transparency Report Jennifer Taubert

More from Johnson & Johnson

What are clinical trials?

Behind every innovative medicine, treatment and therapy is a clinical trial. To help you understand them better, here’s a closer look at how they work.

Meet two Johnson & Johnson nurse educators dedicated to teaching cancer care providers

Jennifer Huff and Jacqui Mellott are two of Johnson & Johnson’s oncology clinical educators—a team of 50 nurses who visit hospitals and infusion centers to help providers understand and stay up to date with treatments.